Search

Displaying results 1621 - 1630 of 10000 in total
  1. Drug

    Tecovirimat

    go.drugbank.com/drugs/DB12020
    ApprovedInvestigational

    [A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. … [L3626, L3614] Tecovirimat was later approved by Health Canada in December 2021,[L39397] followed by the approval from the European Commission in January 2022.

  2. Drug

    Deslanoside

    go.drugbank.com/drugs/DB01078
    Approved

    Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Xanthinol

    go.drugbank.com/drugs/DB09092
    ApprovedWithdrawn

    [L1080] It was approved as a drug in 1998 in Canada and nowadays its status is cancelled post marketing. … [L1079] Xaninthol is known to be a potent vasodilator that can easily pass through the cell membrane and once inside the cell it causes an increase in glucose metabolism resulting in an increased energy

  4. Drug

    Omalizumab

    go.drugbank.com/drugs/DB00043
    ApprovedInvestigational

    [A39518] Omalizumab was first approved in the US in 2003 [A263507] and in Europe in 2005. … Omalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE).

    Products: XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/1.0ML, XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML
  5. Drug

    Ioxilan

    go.drugbank.com/drugs/DB09135
    ApprovedWithdrawn

    Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant

    Categories: Compounds used in a research, industrial, or household settingSynonyms: N-(2,3-dihydroxypropyl)-N’-(2- hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide
  6. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    [A256828] In clinical trials, imlunestrant has been investigated as monotherapy and in combination with other drugs in breast cancer patients.[A256828] … [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway.

  7. Drug

    Colesevelam

    go.drugbank.com/drugs/DB00930
    ApprovedInvestigational

    It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol. … Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood.

  8. Drug

    Retapamulin

    go.drugbank.com/drugs/DB01256
    Approved

    Retapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.

  9. Drug

    Dostarlimab

    go.drugbank.com/drugs/DB15627
    ApprovedInvestigational

    A prospective phase II study in patients with mismatch repair-deficient locally advanced rectal cancer resulted in all twelve patients exhibiting a complete clinical response.[A248905] … , including those of the skin, lung, kidneys, and liver.

  10. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    with Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022. … [L38834] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients